Assessing the Long-Term Safety and Efficacy of Nivolumab Plus Chemotherapy for Broader Clinical Adoption in Advanced GI Cancers

Opinion
Video

Panelists discuss how the adoption of immunotherapy-chemotherapy combinations in clinical practice requires careful consideration of both long-term safety profiles and sustained efficacy data. A 5-year follow-up period generally provides valuable insights into delayed adverse events and durability of response, which helps inform risk-benefit assessments. The balance between safety and efficacy should be evaluated on a patient-specific basis, considering factors such as performance status, comorbidities, and tumor characteristics.

Recent Videos
Advances in perioperative targeted therapies may enable organ preservation and significantly enhance outcomes for patients with gastric cancers.
3 experts are featured in this series.
3 experts are featured in this series.
Related Content